{"url_path":"/sec/txg/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1770787/0001628280-26-032388-index.html","accession_number":"0001628280-26-032388","cik":"0001770787","ticker":"TXG","issuer_name":"10x Genomics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1770787/0001628280-26-032388-index.html","primary_entity_key":"0001770787","primary_entity_name":"10x Genomics, Inc."},"word_count":134,"has_tables":true,"body_markdown":"Item 5.    Other Information.\n\nNone of our directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the quarter ended March 31, 2026, as such terms are defined under Item 408(a) of Regulation S-K, except as follows:\n\nOn March 13, 2026, Shehnaaz Suliman, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 28,616 shares of the Company’s common stock as well additional shares of the Company’s common stock anticipated to be received from potential restricted stock units expected to vest between August 2026 and May 2027, subject to certain conditions. The expiration date of the trading arrangement is June 30, 2027.\n\n22\n\n[Table of Contents](#id818e5dd412c4c208ac607748dd7528f_7)"}